Shots:

• The P-II (AXIOMATIC-SSP) study evaluated milvexian (FXIa inhibitor) vs PBO in a ratio (2:1) in 2366 patients with new symptomatic ischemic stroke or new covert brain infarction who received aspirin & clopidogrel, following an acute ischemic stroke or TIA
• The results showed a 30% relative risk reduction in recurrent symptomatic ischemic strokes in patients who received 25/50/100mg, BID & a dose-response was not observed, no fatal bleeding with no increase in symptomatic intracranial hemorrhage who received 21 days of dual antiplatelet therapy, followed by single antiplatelet therapy
• The rate of major bleeding for 25mg, qd & BID was similar to PBO. The company is expected to initiate the P-III study in 2023

Ref: Businesswire | Image: BMS